Comtan Related Published Studies
Well-designed clinical trials related to Comtan (Entacapone)
Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome. [2007.11]
Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease. [2007]
Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. [2006.06.27]
Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. [2005.05]
Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. [2005.01]
Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. [2005]
Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. [2004.10]
Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug. [2004.09]
Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study. [2004.09]
Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome. [2004.06]
Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients. [2004.02]
Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. [2003.08]
Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study. [2003.03]
Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose. [2002.10]
The effect of COMT inhibition with entacapone on cardiorespiratory responses to exercise in patients with Parkinson's disease. [2002.06]
Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin. [2002.05]
Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). [2002.04]
COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease. [2002.02.26]
Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States. [2002]
The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease. [2001.05]
Twelve-month safety of entacapone in patients with Parkinson's disease. [2001.01]
The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease. [2001.01]
The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. [2000.05]
Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. [1998.11]
Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone. [1998.07]
A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. [1996.08]
Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. [1996.01]
Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: lack of interactions. [1996]
COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers. [1996]
The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine. [1995.08]
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. [1995.02]
Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. [1994.02]
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. [1993]
Well-designed clinical trials possibly related to Comtan (Entacapone)
Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. [2008.01]
Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. [2008]
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. [2005.03.12]
Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy. [1998.07]
Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers. [1996.04]
Other research related to Comtan (Entacapone)
Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial). [2008.10.31]
Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. [2008.10.07]
Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort. [2008.07]
Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease. [2008.06]
Bimodal administration of entacapone in Parkinson's disease patients improves motor control. [2008.03]
Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease. [2008.03]
Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease. [2008.02.08]
The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates. [2007.12]
Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease. [2007.11]
Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off. [2007.08.15]
Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease. [2007.06.14]
Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing-off. [2007.05.21]
Entacapone improves complex movement performance in patients with Parkinson's disease. [2007.05]
Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention. [2007.03]
Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients. [2007.01]
Entacapone Prolongs the Reduction of PLM by Levodopa/Carbidopa in Restless Legs Syndrome. [2007]
Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy. [2006.12]
Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy. [2006.10.16]
Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease. [2006.10]
The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status. [2006.05]
Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats. [2006.05]
Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson disease patients. [2006.03]
High-performance liquid chromatography method for the quantification of entacapone in human plasma. [2005.09.05]
Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off. [2005.07]
Entacapone in the treatment of Parkinson's disease. [2005.06]
Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients. [2005.06]
[Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination.] [2005.05]
The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration. [2005.04]
Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats. [2005.03]
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. [2005.03]
An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. [2005.02]
Clinical advantages of COMT inhibition with entacapone - a review. [2004.10]
Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study. [2004.08]
Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo). [2004.07]
Frequency, reasons, and risk factors of entacapone discontinuation in Parkinson disease. [2004.05]
Levodopa/carbidopa/entacapone (Stalevo). [2004.01.13]
Levodopa therapy with entacapone in daily clinical practice: results of a post-marketing surveillance study. [2004.01]
Entacapone protects from angiotensin II-induced inflammation and renal injury. [2003.12]
The use of entacapone in patients with advanced Parkinson's disease: 2 years' experience. [2003.10]
Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study. [2003.09]
Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease. [2003.08]
The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. [2003.03]
Sleep attacks in Parkinson's disease induced by Entacapone, a COMT-inhibitor. [2003.02]
Excessive daytime sleepiness and 'sleep attacks' induced by entacapone. [2003.02]
Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. [2003.02]
Entacapone-induced hepatotoxicity and hepatic dysfunction. [2002.11]
[Entacapone for treatment of motor fluctuations in idiopathic Parkinson syndrome] [2002.08]
Entacapone does not induce conformational changes in liver mitochondria or skeletal muscle in vivo. [2002.07]
Entacapone in the management of Parkinson's disease. [2002.07]
Pharmacodynamic response of entacapone in rats after administration of entacapone formulations and prodrugs with varying bioavailabilities. [2002.06]
Entacapone in restless legs syndrome. [2002.03]
Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys. [2002]
Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease. [2001.09]
Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis. [2001.07]
Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. [2001.06]
[Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)] [2001.02]
Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. [2001.01]
Switch-over from tolcapone to entacapone in severe Parkinson's disease patients. [2001]
Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study. [2001]
Entacapone and selegiline with L-dopa in patients with Parkinson's disease: an interaction study. [2000.10.01]
Entacapone. [2000.09]
The role of entacapone in the management of Parkinson's disease. [2000.04]
[Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone] [2000.02]
|
